Skip to main content

Breast Cancer

Ausgabe 5/2023

Inhalt (17 Artikel)

Review Article

miR-4796 enhances the sensitivity of breast cancer cells to ionising radiation by impairing the DNA repair pathway

Ting Jiang, Jinfeng Chen, Zhenzhen Wang, Xiaofei Wang, Jun Ma, Fei Zhao, Chen Huang, Yanke Chen

Open Access Original Article

An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers

Reiko Fukui, Takahiro Watanabe, Koji Morimoto, Yukie Fujimoto, Masayuki Nagahashi, Eri Ishikawa, Seiichi Hirota, Yasuo Miyoshi

Original Article

Role of circ-FOXO3 and miR-23a in radiosensitivity of breast cancer

Elahe Abdollahi, Hossein Mozdarani, Behrooz Z. Alizadeh

Original Article

Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cells

Takako Sakamoto, Keiji Tanimoto, Hidetaka Eguchi, Shunta Sasaki, Kouki Tsuboi, Shin-ichi Hayashi, Sahoko Ichihara

Original Article

Radiation-induced angiosarcoma of the breast: individual participant meta-analysis of Japanese population

Yuri Takehara, Naoko Matsuda, Daiki Kobayashi, Atsushi Yoshida, Junko Takei, Naoki Kanomata, Hiroko Tsunoda, Hideko Yamauchi, Naoki Hayashi

Original Article

Interleukin (IL)-17A in triple-negative breast cancer: a potent prognostic factor associated with intratumoral neutrophil infiltration

Freeha Khalid, Kiyoshi Takagi, Ai Sato, Mio Yamaguchi, Fouzia Guestini, Yasuhiro Miki, Minoru Miyashita, Hisashi Hirakawa, Yasuyo Ohi, Yoshiaki Rai, Yasuaki Sagara, Hironobu Sasano, Takashi Suzuki

Open Access Original Article

KLF11 is an independent negative prognostic factor for breast cancer from a cohort study and induces proliferation and inhibits apoptosis in vitro

Lili Lin, Kristina Pfender, Nina Ditsch, Christina Kuhn, Martina Rahmeh, Lin Peng, Elisa Schmoeckel, Doris Mayr, Fabian Trillsch, Sven Mahner, Mirjana Kessler, Udo Jeschke, Anna Hester

Original Article

What affects women’s decision-making on breast reconstruction after mastectomy for breast cancer?

Sara van Bekkum, Marloes E. Clarijs, Fientje J. C. van der Veen, Joost van Rosmalen, Linetta B. Koppert, Marian B. E. Menke-Pluijmers

Open Access Original Article

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia

Michael Rainone, Carolyn E. Behrendt, Saro Kasparian, Tina Nguyen, Mina S. Sedrak, Sayeh Lavasani, Daphne B. Stewart, Yuan Yuan, Joanne E. Mortimer, James R. Waisman, Niki Patel, Vinod Pullarkat

Open Access Original Article

Quality of life and satisfaction of patients after oncoplastic or traditional breast-conserving surgery using the BREAST-Q (BCT module): a prospective study

M. Ghilli, M. D. Mariniello, F. Ferrè, R. Morganti, E. Perre, R. Novaro, L. Colizzi, V. Camilleri, G. Baldetti, E. Rossetti, L. Coletti, C. Scatena, M. Ghilardi, M. C. Cossu, M. Roncella

Original Article

Association of psychological distress with arm morbidity symptoms in breast cancer survivors: outcomes from the use of PHQ-9 and GAD-7 questionnaires

Khairunnisa’ Md Yusof, Sherina Mohd Sidik, Rozi Mahmud, Maha Abdullah, Kelly A. Avery-Kiejda, Rozita Rosli

Open Access Original Article

Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives

Sumito Saeki, Tsuguo Iwatani, Atsuko Kitano, Naomi Sakurai, Yuko Tanabe, Chikako Yamauchi, Ataru Igarashi, Yusuke Kajimoto, Sayaka Kuba, Fumikata Hara, Yasuaki Sagara, Shinji Ohno

Open Access Correction

Correction: Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives

Sumito Saeki, Tsuguo Iwatani, Atsuko Kitano, Naomi Sakurai, Yuko Tanabe, Chikako Yamauchi, Ataru Igarashi, Yusuke Kajimoto, Sayaka Kuba, Fumikata Hara, Yasuaki Sagara, Shinji Ohno

Open Access Original Article

An integrated analysis of microRNAs regulating DNA damage response in triple-negative breast cancer

Raviprasad Kuthethur, Maria Sona Jerome, Yashwanth Subbannayya, Sanjiban Chakrabarty

Original Article

The transverse myocutaneous gracilis flap (TMG) for breast reconstruction: ipsi vs. contralateral harvest—aesthetic outcome and refinement procedures

Felix H. Vollbach, Clara Neuss, Laura C. Siegwart, Amir K. Bigdeli, Ulrich Kneser, Hisham Fansa, Dimitra Kotsougiani-Fischer

Original Article

Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer

Yoko Suzuki, Takayuki Iwamoto, Maya Uno, Minami Hatono, Yukiko Kajiwara, Yuko Takahashi, Mariko Kochi, Tadahiko Shien, Yuichiro Kikawa, Yukari Uemura, Yasuhiro Hagiwara, Seiichiro Yamamoto, Naruto Taira, Hiroyoshi Doihara, Shinichi Toyooka

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.